TrapEase IVC filter found to have higher rate of complications
The TrapEase inferior vena cava filter (IVC filter) has been found to have a higher rate of symptomatic thrombosis than alternative IVC filters. Manufacturer by Johnson & Johnson, the TrapEase IVC filter has been on the market since 2000 and has undergone significantly fewer studies than alternative IVC filters.
The TrapEase IVC has been found to have a higher rate of blood clots. In a trial of 157 patients, researchers encountered 37 cases of gastrointestinal bleeding, 12 cases of intracranial hemorrhage, 19 cases of free-floating blood clots and 19 cases of failure to anticoagulated, in addition to the 5 cases of thrombosis, which can lead to pulmonary embolism. Despite the prevalence of IVC filters since 1967, this was the first trial to compare filters.
The TrapEase filter has also been found to fracture when being removed at a higher rate than expected. Patients who received a TrapEase IVC filter have begun filing lawsuits against Johnson & Johnson alleging that the company failed to warn them about the increased risk of severe complications associated with the device.